Institute Catalá Oncología -ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2024

  1. Access to melanoma drugs in Spain: a cross-sectional survey

    Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583

2023

  1. SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry

    Clinical and Translational Oncology, Vol. 25, Núm. 3, pp. 768-775

2020

  1. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

    Science Translational Medicine, Vol. 12, Núm. 565

2017

  1. Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program

    Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 761-768

2016

  1. Phase II multi-centre, non randomized, open label study of nivolumab in combination with ipilimumab as first line in adults patients with metastatic uveal melanoma. GEM 14-02

    Annals of Oncology, Vol. 27, pp. vi377

2015

  1. Frequency and characteristics of familial melanoma in Spain: The FAM-GEM-1 study

    PLoS ONE, Vol. 10, Núm. 4